Intra-prostatic Fiducial markers and concurrent androgen deprivation

Clinical Oncology

Volumn 17, Issue 6, 2005, Pages 465-468

  Nichol, A M ^a   Rosewall, T ^a   Catton, C N ^a   Jaffray, D A ^a   Warde, Padraig R ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Androgen deprivation; Fiducial markers; Prostate adenocarcinoma

Indexed keywords

ANDROGEN; ANTIANDROGEN; GOLD; GONADORELIN AGONIST; TUMOR MARKER;

ADULT; ARTICLE; BLADDER WALL; CANCER HORMONE THERAPY; CASE REPORT; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER SIMULATION; COMPUTER SYSTEM; DOSE CALCULATION; DOSIMETRY; GLEASON SCORE; HISTOGRAM; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RECTUM; THREE DIMENSIONAL IMAGING;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANDROGENS; BIOLOGICAL MARKERS; DOSE FRACTIONATION; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; TOMOGRAPHY, X-RAY COMPUTED;

EID: 23744458118     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2005.06.002     Document Type: Article

References (10)

1. M. Bolla L. Collette L. Blank P. Warde J.B. Dubois R.O. Mirimanoff et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial Lancet 360 2002 103-106
2. R.J. Shearer J.H. Davies J.S. Gelister D.P. Dearnaley Hormonal cytoreduction and radiotherapy for carcinoma of the prostate Br J Urol 69 1992 521-524
3. M. Liu T. Pickles A. Agranovich E. Berthelet G. Duncan M. Keyes et al. Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy Int J Radiat Oncol Biol Phys 58 2004 59-67
4. P.W. Chung T. Haycocks T. Brown Z. Cambridge V. Kelly H. Alasti et al. On-line aSi portal imaging of implanted fiducial markers for the reduction of interfraction error during conformal radiotherapy of prostate carcinoma Int J Radiat Oncol Biol Phys 60 2004 329-334
5. J. Pouliot M. Aubin K.M. Langen Y.M. Liu B. Pickett K. Shinohara et al. (Non)-migration of radiopaque markers used for on-line localization of the prostate with an electronic portal imaging device Int J Radiat Oncol Biol Phys 56 2003 862-866
6. J.M. Crook Y. Raymond D. Salhani H. Yang B. Esche Prostate motion during standard radiotherapy as assessed by fiducial markers Radiother Oncol 37 1995 35-42
7. M.E. Gleave S.L. Goldenberg J.L. Chin J. Warner F. Saad L.H. Klotz et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: Biochemical and pathological effects J Urol 166 2001 500-506 [discussion 506-507]
8. J. Crook C. Ludgate S. Malone J. Lim G. Perry L. Eapen et al. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer Int J Radiat Oncol Biol Phys 60 2004 15-23
9. G.S. Merrick W.M. Butler K.E. Wallner J.H. Lief R.L. Anderson B.J. Smeiles et al. The importance of radiation doses to the penile bulb vs. crura in the development of postbrachytherapy erectile dysfunction Int J Radiat Oncol Biol Phys 54 2002 1055-1062
10. M. Roach K. Winter J.M. Michalski J.D. Cox J.A. Purdy W. Bosch et al. Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: Findings from a prospective, multi-institutional, phase I/II dose-escalation study Int J Radiat Oncol Biol Phys 60 2004 1351-1356